→ Novartis CEO Vas Narasimhan is raising some eyebrows today as he discusses the future of Sandoz, the pharma giant’s big generics unit. “We consider Sandoz an integral part of Novartis, we’re focused on transforming the business, making it an autonomous entity over the next 18 months that is able to compete as an independent unit within Novartis,” he told analysts, according to a report in Reuters. “After we complete all that, then I think we can have further conversations about where we want to head from there.”
→ Narasimhan, though, has no second thoughts about the way he wants Novartis to “reimagine” medicine. He’s been showing off the company’s new digital nerve center, which is charged with monitoring some 500 clinical trials the company is engaged in.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,000+ biopharma pros who read Endpoints News by email every day.Free Subscription